Jeffrey Smith, a dermatologist, is seeking investor advice at Harvard’s “Guppy Tank” for a new drug aimed at increasing protective melanin in the skin. This drug could improve life for those highly sensitive to sunlight, like porphyria patients who suffer burns quickly.<\/p>\n
Smith, an assistant professor at Harvard Medical School and dermatologist at Brigham and Women\u2019s Hospital, is considering which conditions to target in early trials and any overlooked aspects of his skin pigmentation antibody. At “Guppy Tank,” Harvard’s spin on “Shark Tank,” Smith presented his idea, co-developed with Andrew Kruse, to four investors who provided feedback without the intense pressure typical of the TV show.<\/p>\n
Smith pitched a melanocortin-1 receptor agonist that tans the skin. This new treatment, unlike an existing drug that causes nausea and requires frequent implants, offers a less invasive option with biannual injections. Smith envisions uses for skin-cancer prevention and conditions like xeroderma pigmentosum (XP), which currently lacks approved treatments. He also sees potential for treating transplant recipients with elevated cancer risks.<\/p>\n
Investors raised questions about drug targeting, dosing, and insurance implications. Mike Schlabach from Curie Bio noted that if animal models show reduced nausea, it could be a significant improvement. He also mentioned that insurers might prefer simpler solutions if the drug doesn’t show vastly better outcomes.<\/p>\n
Elias Quijano from Northpond Ventures inquired about other mechanisms of action beyond melanin production. Smith responded that early research suggests cancer protection beyond skin darkening. Gunes Bozkurt from Beiersdorf questioned dosage modulation, to which Smith replied that priorities differ between cosmetic and medical needs.<\/p>\n
Chaya Patel from Mission BioCapital asked about future trials. Smith expressed interest in comparing their drug to existing treatments, citing XP as a possible initial target due to its higher incidence in Japan, where focused trials could be conducted.<\/p>\n
Unlike “Shark Tank,” the “Guppy Tank” session ended without dramatic conclusions or company sales, as no company exists yet. However, the feedback gathered is expected to be beneficial as Smith and Kruse progress in their drug development journey.<\/p>\n